Glaritus

Insulin glargine

DM in adults, adolescents & childn ≥2 yr.

SC Individualized dosage once daily, same time each day. Inj sites must be rotated w/in given inj area from 1 inj to the next. Type 2 DM May be given w/ other oral antidiabetic medicinal products.

Hypersensitivity. During episodes of hypoglycemia.

Not to be administered IV. Not the insulin of choice for the treatment of diabetic ketoacidosis. Hyper- & hypoglycaemic episodes. Intensify blood glucose & metabolic monitoring. Caution in patients in whom hypoglycaemic episodes might be of clinical relevance (eg, patients w/ significant stenoses of the coronary arteries or of the blood vessels supplying the brain as well as in patients w/ proliferative retinopathy, particularly if not treated w/ photocoagulation; patients w/ diminished warning symptoms of hypoglycaemia (eg, patients in whom glycaemic control is markedly improved, in whom hypoglycaemia develops gradually, elderly, after transfer from animal to human insulin, in whom an autonomic neuropathy is present, w/ a long history of DM, suffering from a psychiatric illness, receiving concurrent certain medicinal products). Prolonged effect may delay recovery from hypoglycaemia. Increased susceptibility to hypoglycaemia in case of change in inj area; improved insulin sensitivity; unaccustomed, increased or prolonged physical activity; intercurrent illness; inadequate food intake; missed meals; alcohol consumption; certain uncompensated endocrine disorders; concomitant treatment w/ certain other medicinal products. Hyperglycaemia may occur under certain circumstances including omission/reduction of inj or decrease in insulin effectiveness, pen malfunction; decreased physical activity, stress situations, injuries, operations, feverish illnesses or certain other diseases; concurrent use of other medicines. Insulin requirement may be diminished in patients w/ renal or hepatic impairment. Maintain good metabolic control during pregnancy in women w/ preexisting or gestational diabetes. Decrease insulin requirements during 1st trimester & generally increase during 2nd & 3rd trimesters. Lactation. Ped <2 yr. Elderly ≥65 yr.

Hypoglacaemia; temporary visual impairment, diabetic retinopathy; lipodystrophy; inj site & allergic reactions (eg, redness, pain, itching, hives, swelling or inflammation), immediate-type allergic reactions (eg, generalized skin reactions, angioedema, bronchospasm, hypotension & shock).

Increased risk of hypoglycemia w/ antidiabetic agents, ACE inhibitors, ARBs, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, pramlintide, propoxyphene, salicylates, somastatin analogs (eg, octreotide), sulfonamide antibiotics. Decreased blood glucose-lowering effect w/ atypical antipsychotics (eg, olanzapine & clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, INH, niacin, OCs, phenothiazines, progestogens (eg, in OCs), PIs, somatropin, sympathomimetic agents (eg, albuterol, epinephrine, terbutaline), thyroid hormones. Increased or decreased blood glucose-lowering effect w/ alcohol, β-blockers, clonidine, lithium salts. Hypoglycemia may sometimes followed by hyperglycemia w/ pentamidine. Blunted signs & symptoms of hypoglycemia w/ β-blockers, clonidine, guanethidine, reserpine.

Insulin Preparations

A10AE04 - insulin glargine ; Belongs to the class of long-acting insulins and analogues for injection. Used in the treatment of diabetes.

K